# OnCo record ds-3201b-atll-phase-2 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/ds-3201b-atll-phase-2/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "ds-3201b-atll-phase-2", "NCT04102150" ;
  schema:name "EZH1 and EZH2 inhibitor DS-3201b in relapsed adult T-cell leukaemia/lymphoma"@en ;
  schema:alternateName "DS-3201b in ATL"@en, "Izutsu 2023"@en ;
  schema:description "A tablet that blocks two enzymes controlling which genes are switched on shrank the disease in about half of people with relapsed adult T-cell leukaemia, nearly all of whom had already had mogamulizumab."@en ;
  schema:url <https://onco.cc/trials/ds-3201b-atll-phase-2/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04102150>, <https://doi.org/10.1182/blood.2022016862> ;
  onco:status "positive" ;
  onco:tag "lymphoma-evidence-entities" ;
  onco:phase "2" ;
  schema:startDate "2019-11-21" ;
  onco:cancers <https://onco.cc/cancers/adult-t-cell-leukaemia-lymphoma/>, <https://onco.cc/cancers/peripheral-t-cell-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/epigenetics/> ;
  onco:technologies <https://onco.cc/technologies/epigenetic-drugs/> ;
  onco:targets <https://onco.cc/targets/ezh2/> ;
  onco:companies <https://onco.cc/companies/daiichi-sankyo/> ;
  onco:terms <https://onco.cc/terms/orr/>, <https://onco.cc/terms/lymphoma-htlv-1/> ;
  onco:trials <https://onco.cc/trials/mogamulizumab-atll-phase-2-japan/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-izutsu-ezh1-ezh2-inhibitor-atll-blood-2023/> .